ArticleJournal of oncology2013
Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.
Article in Journal of oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 47 citations in OpenAlex.
- Transcriptome Derived Artificial neural networks predict PRRC2A as a potent biomarker for epilepsy.Journal, genetic engineering & biotechnology · 2025Article
- Integrative multi-omics and systems bioinformatics in translational neuroscience: A data mining perspective.Journal of pharmaceutical analysis · 2023Review
- Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2021Review
- Article
- Man's best friend in life and death: scientific perspectives and challenges of dog brain banking.GeroScience · 2021Review
- The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.Journal of translational medicine · 2019Article
- Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.Seminars in oncology · 2015Review
- From Molecules to Patients: The Clinical Applications of Translational Bioinformatics.Yearbook of medical informatics · 2015Article
- Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine.Journal of clinical bioinformatics · 2015Article
- Introducing Biospecimen Science to Communities: Tools from Two Cities.Progress in community health partnerships : research, education, and action · 2015Article
- Engaging diverse populations about biospecimen donation for cancer research.Journal of community genetics · 2014Article
- Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine?Journal of visualized experiments : JoVE · 2014Article
- Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.Frontiers in genetics · 2014Review
- Colorectal Cancer: Basic and Translational Research.Gastrointestinal tumors · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and "-omics" data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. The approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking, bioinformatics, and electronic medical records (EMRs). The analytical power of bioinformatic platforms combined with patient clinical data from EMRs can reveal potential biomarkers and clinical phenotypes that allow researchers to develop experimental strategies using selected patient biospecimens stored in tissue banks. For cancer, high-quality biospecimens collected at diagnosis, first relapse, and various treatment stages provide crucial resources for study designs. To enlarge biospecimen collections, patient education regarding the value of specimen donation is vital. One approach for increasing consent is to offer publically available illustrations and game-like engagements demonstrating how wider sample availability facilitates development of novel therapies. The critical value of tissue bank samples, bioinformatics, and EMR in the early stages of the biomarker discovery process for personalized medicine is often overlooked. The data obtained also require cross-disciplinary collaborations to translate experimental results into clinical practice and diagnostic and prognostic use in personalized medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.